Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages 185-192 , December 2010

An Open-Label Pilot Study Evaluating by Magnetic Resonance Imaging the Potential for a Disease-Modifying Effect of Celecoxib Compared to a Modelized Historical Control Cohort in the Treatment of Knee Osteoarthritis

  • Jean-Pierre Raynauld, MD

      Affiliations

    • Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
    • ,
  • Johanne Martel-Pelletier, PhD

      Affiliations

    • Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
    • ,
  • André Beaulieu, MD

      Affiliations

    • Faculty of Medicine, Laval University, Quebec, Quebec, Canada
    • ,
  • Louis Bessette, MD

      Affiliations

    • Groupe de Recherche en Rhumatologie et Maladies Osseuses, Sainte-Foy, Quebec, Canada
    • ,
  • Frédéric Morin, MD

      Affiliations

    • Centre de Recherche Musculo-squelettique, Trois-Rivières, Quebec, Canada
    • ,
  • Denis Choquette, MD

      Affiliations

    • Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
    • ,
  • Boulos Haraoui, MD

      Affiliations

    • Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
    • ,
  • François Abram, PhD

      Affiliations

    • ArthroVision Inc., Montreal, Quebec, Canada
    • ,
  • Jean-Pierre Pelletier, MD

      Affiliations

    • Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
    • Corresponding Author InformationAddress reprint requests to Jean-Pierre Pelletier, MD, Director, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, 1560 Sherbrooke Street East, Montreal, Quebec H2L 4M1, Canada

References 

  1. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–1155
  2. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7:R644–R665
  3. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis (Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence). Osteoarthritis Cartilage. 2007;15:981–1000
  4. Tindall EA, Sharp JT, Burr A, Katz TK, Wallemark CB, Verburg K, et al. A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib. Clin Ther. 2002;24:2051–2063
  5. Mastbergen SC, Lafeber FP, Bijlsma JW. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford). 2002;41:801–808
  6. Raynauld J-P, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009;68:938–947
  7. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Labonté F, Beaudoin G, de Guise JA, et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over 2 years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum. 2004;50:476–487
  8. Bingham CO, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the 2-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006;54:3494–3507
  9. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Beaudoin G, Choquette D, Haraoui B, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2006;8:R21
  10. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403–3412
  11. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low—results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8:R66
  12. Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis. 2007;66:880–885
  13. Lunt M, Solomon D, Rothman K, Glynn R, Hyrich K, Symmons DP, et al. Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol. 2009;169:909–917
  14. Altman RD, Asch E, Bloch DA, Bole G, Borenstein D, Brandt KD, et al. Development of criteria for the classification and reporting of osteoarthritis (Classification of osteoarthritis of the knee). Arthritis Rheum. 1986;29:1039–1049
  15. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthosis. Ann Rheum Dis. 1957;16:494–502
  16. Kauffmann C, Gravel P, Godbout B, Gravel A, Beaudoin G, Raynauld J-P, et al. Computer-aided method for quantification of cartilage thickness and volume changes using MRI: validation study using a synthetic model. IEEE Trans Biomed Eng. 2003;50:978–988
  17. Felson DT, McLaughlin S, Goggins J, LaValley MP, Gale ME, Totterman S, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med. 2003;139:330–336
  18. Berthiaume MJ, Raynauld JP, Martel-Pelletier J, Labonté F, Beaudoin G, Bloch DA, et al. Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis. 2005;64:556–563
  19. Hunter DJ, Zhang Y, Niu J, Goggins J, Amin S, LaValley MP, et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum. 2006;54:1529–1535
  20. Raynauld J-P, Martel-Pelletier J, Berthiaume M-J, Abram F, Choquette D, Haraoui B, et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis. 2008;67:683–688
  21. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a 3-year, placebo-controlled trial (Evaluation of the chondromodulating effect of diacerein in OA of the hip). Arthritis Rheum. 2001;44:2539–2547
  22. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251–256
  23. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162:2113–2123
  24. Brandt KD, Mazzuca SA. Lessons learned from 9 clinical trials of disease-modifying osteoarthritis drugs. Arthritis Rheum. 2005;52:3349–3359
  25. Cicuttini FM, Wluka AE, Stuckey SL. Tibial and femoral cartilage changes in knee osteoarthritis. Ann Rheum Dis. 2001;60:977–980
  26. Wluka AE, Wolfe R, Stuckey S, Cicuttini FM. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis?. Ann Rheum Dis. 2004;63:264–268
  27. Huskisson EC, Berry H, Gishen P, Jubb RW, Whitehead J. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee (LINK Study Group Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis). J Rheumatol. 1995;22:1941–1946

 J.P. Raynauld is a consultant for ArthroVision Inc. J. Martel-Pelletier and J.P. Pelletier are consultants for and holders of stocks in ArthroLab Inc. and ArthroVision Inc. A. Beaulieu, L. Bessette, F. Morin, D. Choquette, and B. Haraoui received honoraria from ArthroLab Inc. F. Abram is an employee of ArthroVision Inc.

PII: S0049-0172(09)00145-0

doi: 10.1016/j.semarthrit.2009.10.003

Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages 185-192 , December 2010

Article Tools